HK1259439A1 - 確定體細胞誘變原因的方法 - Google Patents

確定體細胞誘變原因的方法

Info

Publication number
HK1259439A1
HK1259439A1 HK19101843.6A HK19101843A HK1259439A1 HK 1259439 A1 HK1259439 A1 HK 1259439A1 HK 19101843 A HK19101843 A HK 19101843A HK 1259439 A1 HK1259439 A1 HK 1259439A1
Authority
HK
Hong Kong
Prior art keywords
determining
methods
cause
somatic mutagenesis
somatic
Prior art date
Application number
HK19101843.6A
Other languages
English (en)
Inventor
Robyn Alice Lindley
Original Assignee
Gmdx Co Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012904826A external-priority patent/AU2012904826A0/en
Application filed by Gmdx Co Pty Ltd filed Critical Gmdx Co Pty Ltd
Publication of HK1259439A1 publication Critical patent/HK1259439A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
HK19101843.6A 2012-11-05 2019-02-01 確定體細胞誘變原因的方法 HK1259439A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012904826A AU2012904826A0 (en) 2012-11-05 Method for the diagnosis of disease associated with somatic mutagenesis
AU2012904940A AU2012904940A0 (en) 2012-11-13 Database system and method for the diagnosis of disease associated with somatic mutagenesis
AU2013901253A AU2013901253A0 (en) 2013-04-12 Method for the diagnosis of disease associated with mutagenesis using small numbers of somatic mutations

Publications (1)

Publication Number Publication Date
HK1259439A1 true HK1259439A1 (zh) 2019-11-29

Family

ID=50626228

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16102679.6A HK1214842A1 (zh) 2012-11-05 2016-03-09 確定體細胞突變原因的方法
HK19101843.6A HK1259439A1 (zh) 2012-11-05 2019-02-01 確定體細胞誘變原因的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK16102679.6A HK1214842A1 (zh) 2012-11-05 2016-03-09 確定體細胞突變原因的方法

Country Status (8)

Country Link
US (4) US10767229B2 (zh)
EP (2) EP2914750B1 (zh)
JP (2) JP6304776B2 (zh)
CN (1) CN104903467B (zh)
AU (1) AU2013337616B2 (zh)
ES (1) ES2674928T3 (zh)
HK (2) HK1214842A1 (zh)
WO (1) WO2014066955A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11225690B2 (en) 2015-08-26 2022-01-18 Gmdx Co Pty Ltd Methods of detecting cancer recurrence
SG11201901432YA (en) 2016-08-25 2019-03-28 Nantomics Llc Immunotherapy markers and uses therefor
WO2018223185A1 (en) * 2017-06-06 2018-12-13 Gmdx Co Pty Ltd Methods of determining the likelihood of hepatitis b virus recrudescence
US20200362418A1 (en) * 2017-10-02 2020-11-19 Curematch, Inc. Method of prediction of tumor-derived neo-peptide antigenicity and/or immunogenicity using mutational signature patterns
SG11202003885UA (en) 2017-11-08 2020-05-28 Twinstrand Biosciences Inc Reagents and adapters for nucleic acid sequencing and methods for making such reagents and adapters
WO2019095017A1 (en) * 2017-11-17 2019-05-23 Gmdx Co Pty Ltd Systems and methods for predicting the efficacy of cancer therapy
WO2019160998A1 (en) * 2018-02-13 2019-08-22 Twinstrand Biosciences, Inc. Methods and reagents for detecting and assessing genotoxicity
TW202012639A (zh) * 2018-04-24 2020-04-01 美商格瑞爾公司 使用病原體核酸負荷確定個體是否患有癌症病況的系統及方法
WO2020014693A1 (en) 2018-07-12 2020-01-16 Twinstrand Biosciences, Inc. Methods and reagents for characterizing genomic editing, clonal expansion, and associated applications
WO2021077176A1 (en) * 2019-10-25 2021-04-29 Gmdx Co Pty Ltd Methods for diagnosis and treatment
US20230242992A1 (en) * 2020-06-01 2023-08-03 Gmdx Co Pty Ltd Methods of predicting cancer progression

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
EP0880508B1 (en) 1996-02-13 2003-04-16 AstraZeneca AB Quinazoline derivatives as vegf inhibitors
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
KR20030013433A (ko) 2000-05-31 2003-02-14 아스트라제네카 아베 혈관 손상 활성을 가진 인돌 유도체
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
AU6623301A (en) 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
AU2003903430A0 (en) * 2003-07-04 2003-07-17 Johnson & Johnson Research Pty Limited Method for detection of alkylated cytosine in dna
WO2012071096A2 (en) * 2010-09-03 2012-05-31 The Johns Hopkins University Arid1a and ppp2r1a mutations in cancer

Also Published As

Publication number Publication date
CN104903467B (zh) 2020-09-08
EP2914750B1 (en) 2018-04-18
AU2013337616B2 (en) 2019-03-21
JP6304776B2 (ja) 2018-04-04
JP2016505241A (ja) 2016-02-25
ES2674928T3 (es) 2018-07-05
CN104903467A (zh) 2015-09-09
JP2018108105A (ja) 2018-07-12
US20230138572A1 (en) 2023-05-04
EP2914750A4 (en) 2016-07-13
AU2013337616A1 (en) 2015-07-02
US20150284803A1 (en) 2015-10-08
EP3354752A1 (en) 2018-08-01
US10767229B2 (en) 2020-09-08
US20180334725A1 (en) 2018-11-22
WO2014066955A1 (en) 2014-05-08
US20200362422A1 (en) 2020-11-19
JP6490849B2 (ja) 2019-03-27
EP2914750A1 (en) 2015-09-09
EP3354752B1 (en) 2020-03-11
HK1214842A1 (zh) 2016-08-05

Similar Documents

Publication Publication Date Title
HK1259439A1 (zh) 確定體細胞誘變原因的方法
HK1250690A1 (zh) 方法
HK1208363A1 (zh) 新方法
EP2836211A4 (en) NOVEL PROCEDURE
GB2519934B (en) Improved shisha
ZA201405746B (en) Rafamycin analogs and methods for making same
HK1217735A1 (zh) 用於單分子分析的方法
HK1205320A1 (zh) 確定關係值的工具和方法
IL253988B (en) Acylation methods of maytansinol
GB2507760B (en) Methods
GB201208874D0 (en) Methods
GB201317355D0 (en) Mutation Analysis
GB201204280D0 (en) Methods
HK1205321A1 (zh) 確定關係值的工具和方法
GB201208756D0 (en) Methods
GB2504945B (en) Channel quality indicator
GB201220686D0 (en) Methods
AP2012000550S (en) E-horn methods
GB201216074D0 (en) Methods
GB201209689D0 (en) Methods
GB201208963D0 (en) Methods
GB201208875D0 (en) Methods
GB201207793D0 (en) Methods
GB201306192D0 (en) Novel methods